Skip to main content
Premium Trial:

Request an Annual Quote

SGX, Boehringer, Sense Proteomic, Procognia, MDS Proteomics, Lilly, OGS, Wyeth, Fox Foundation, U. Penn, Biosentients, iSentient, NanoInk

Premium

SGX Gets Boehringer Ingelheim Deal

Structural Genomix of San Diego, Calif., and Boehringer Ingelheim Pharmaceuticals said last week they started a two-year collaboration. Under the agreement, SGX will solve the three dimensional structures of protein targets provided by Boehringer. Subsequently, SGX will generate co-crystals with potential drug lead compounds.

Boehringer hopes that SGX's high-throughput protein structure determination platform will help it optimize lead compounds and improve drug candidates.

 

Sense Proteomic Acquired by Procognia

Protein chip manufacturer Sense Proteomic of Cambridge, UK, has been acquired by Procognia of Maidenhead, UK, the companies announced last week.

Sense Proteomic's staff will be integrated into Procognia and will remain at the Babraham Institute in Cambridge for at least another six months.

Procognia, which now has 60 employees, has developed technologies for the analysis of glycosylation patterns on proteins, which will be complemented by Sense's functional array technology, according to the company.

In addition, Procognia closed a $4 million financing round from existing shareholders Apax Partners, Evergreen Partners, and Vitalife, bringing its total funding raised since its foundation in April 2002 to $18.3 million.

 

MDS Proteomics, Lilly Launch Pilot

MDS Proteomics and Eli Lilly Canada, both of Toronto, said last week they had a pilot study to explore the use of MDSP's PhosMap technology. Financial terms of the agreement were not disclosed.

The study will focus on Lilly's drug candidates and is designed to assess the capability of MDSP's technology to determine the effects of kinase inhibitors on kinase targets.

PhosMap enables researchers to study changes in phosphorylation of proteins in response to drug treatment.

 

OGS Signs with Wyeth, Expects Patent

Oxford GlycoSciences of Oxford, UK, has signed a contract with Wyeth Pharmaceuticals of Collegeville, Penn., to provide proteomics services to Wyeth.

Under the agreement, OGS will analyze biological samples from disease-associated and control groups provided by Wyeth to identify biomarkers. Other terms of the agreement, which OGS said is a relatively small collaboration, were not disclosed.

Separately, OGS said last week that it expects to receive a European proteomics patent this quarter, following a notice from the European Patent Office. The patent would cover computer-assisted methods and apparatus for identifying and isolating biomolecules in a biological sample. OGS said it already holds a corresponding patent in the US.

 

Fox Foundation Awards 11 Grants

The Michael J. Fox Foundation for Parkinson's Research has awarded 11 grants totaling over $2.6 million to researchers investigating the role of protein degradation in Parkinson's disease.

One of the projects, led by Richard Palmiter at the University of Washington in Seattle, is entitled “Proteomics Analysis of Accumulated Proteins in Dopaminergic Neurons Using a Mouse Model of Ubiquitin-proteasome System Dysfunction.”

 

U Penn Licenses Protein Atlas from Confirmant

The University of Pennsylvania has licensed The Protein Atlas of the Human Genome from Confirmant of Abington, UK. Financial terms of the agreement were not disclosed.

The multi-year license will give researchers at the university access to this database of experimentally derived, protein-coding genes and their expression in a wide variety of normal and diseased samples.

 

Biosentients Forms New Parent, iSentient

Biosentients of Emeryville, Calif., has become a wholly owned subsidiary of iSentient, a company it created to support the expansion of its platform software and applications to markets outside the life sciences.

Biosentients will continue to focus on the drug discovery market, targeting biotechnology and pharmaceutical companies with applications in molecular biol- ogy. ISentient will focus on other industries that demand seamless management, integration, and analysis using data and applications from globally distributed sources.

 

NanoInk Receives $6M in Second Round

NanoInk of Chicago has closed a $6 million second round of financing led by Lurie Investment Fund.

The company will use the funding to build out its management team, broaden its application-specific development efforts, and accelerate the delivery of DPNWriter, which is scheduled for release during this quarter. NanoInk is developing its patented dip pen nanolithography technology for protein chips and other applications.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.